You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!
Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Research And Development
Stock Price, News, & Analysis for Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH)...
Yahoo FinanceMar 6
Edited Transcript of ICPT earnings conference call or presentation 28-Feb-19 1:30pm GMT
Q4 2018 Intercept Pharmaceuticals Inc Earnings Call New York Mar 7, 2019 (Thomson StreetEvents) -- Edited Transcript of Intercept Pharmaceuticals Inc earnings conference call or presentation Thursday, February 28, 2019 at 1:30:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Jerome B. Durso Int...
The Motley FoolMar 6
Why Intercept Pharmaceuticals Stock Hit the Skids in February
What happened Intercept Pharmaceuticals (NASDAQ:ICPT), a mid-cap drugmaker focusing on diseases of the liver, saw its shares lose 14.5% of their value last month, according to data from S&P Global Market Intelligence. Prior to last month's pullback, Intercept's shares were up by almost 80% over the last 12 months. So what halted Intercept's protracted rally? On Feb. 19 the company reported positive top-line results for obeticholic acid (Ocaliva) in patients with liver fibrosis due to nonalcoholic steatohe...
Expected May 8, Pre-Market